Metabolite Identification (MetID) plays an important role in the field of new drug development. In the lead optimization stage, MetID can help to locate the metabolic soft spots, so that medicinal chemists can make targeted structural modifications to improve the pharmacokinetic characteristic. According to the NMPA and FDA guidelines, the identification and comparison of in vitro metabolites is an important basis for the selection of experimental animal species at the IND-Enabling stage. In addition, reactive metabolites can covalently bind to biological macromolecules in the body, leading to toxic reactions. Therefore, early screening of reactive metabolites by GSH Trapping will help reduce the risk of later development.
Medicilon Metabolite Identification (MetlD) Service Platform
High Resolution Mass Spectrometer (HRMS) is an essential tool for metabolite identification research. The Bioanalysis Department of Medicilon introduced newly installed Thermo Scientific Q Exactive HF-X Quadrupole-Ultra High-Field-Orbitrap Mass Spectrometer, which is one of the most advanced HRMS. Its resolution is up to 240,000 FWHM, and has high-quality accuracy (<1ppm, which can accurately fit the molecular formula), high sensitivity (equipped with a new high-capacity ion transfer tube and electric ion funnel, which can detect nanogram samples), high scanning speed (Up to 40 Hz), high stability (no need to frequently calibrate the mass axis), which is better than the IT-TOF, TripleTOF, QTof, LTQ-Orbitrap, QE Focus and QE Plus, the most common equipment in the industry. For liquid chromatography, Medicilon equips with Thermo Fisher’s Vanquish Flex UHPLC and DAD detector and installs the Thermo Fisher’s Compound Discoverer software for data analysis.
Medicilon’s UHPLC-UV-QE HF-X System
MetID Research Support New Drug Discovery and Filing
The MetID team of Medicilon is composed of experienced scientists. We provide fast and reliable in vivo and in vitro MetID and reactive metabolite capture services. We also support new drug screening and domestic and foreign IND filings. Since the establishment of MetID team, Medicilon has successfully completed a large number of different types of research projects for the clients, including the challenging peptide MetID research.
Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research. Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support. Medicilon grows together with the clients and delivers the new drug research and development services to more than 700 clients globally. Medicilon is proud to contribute to human health in the globe.